Enlisting apoptosis to improve stem cell–based therapies

Cellect Biomed has developed a stem cell selection process it hopes will optimize clinical and research applications of stem cells and provide a boon to the stem cell industry. The company’s ultimate goal is to make stem cell transplantation a safer and more effective medical procedure. To download the full article, please sign in.

Page of
Go to the profile of Cellect Biomed Ltd

Cellect Biomed Ltd

Cellect Biotechnology was founded in 2011 with a mission to become a global leader in the next generation of cellular therapies by developing innovative solutions for immune system regeneration. Achieving higher selectivity, greater specificity and decreased toxicity, Cellect envisions its products becoming an integral and essential part of Bone Marrow Transplantation (BMT), as well as integrated into many aspects of regenerative medicine.

Comments are disabled